Major Immediate Early Promoter (MIEP)

The Major Immediate Early Promoter (MIEP) is a DNA regulatory element within the human cytomegalovirus genome that controls the expression of the IE1-72kDa and IE2-86kDa immediate early proteins, which are essential for viral replication and immune evasion. The MIEP is not itself a therapeutic target, but rather a regulatory sequence whose activity is controlled by epigenetic mechanisms including histone modifications and chromatin remodeling. During viral latency, the MIEP is silenced through histone methylation, while reactivation from latency requires histone acetylation and de-repression of the promoter. Emerging research suggests that alternative intronic promoters may also drive IE gene expression during reactivation. While the MIEP cannot be directly targeted by drugs, understanding its regulation is critical for developing new antiviral strategies, and histone acetyltransferase inhibitors have shown promise in blocking viral reactivation by preventing the epigenetic changes needed to reactivate MIEP function.

Other names

Major immediate early promoter of human cytomegalovirusHCMV major immediate early promoterMIE promoter

Rather than drugs acting on the MIEP, antiviral strategies target the IE proteins (IE1 and IE2) that the MIEP produces. The MIEP regulation involves: Epigenetic silencing through histone methylation and heterochromatin protein 1 recruitment during latency; Reactivation through histone acetylation and reversal of repressive histone modifications; Alternative intronic promoters (ip1 and ip2) within the MIE region that may support viral reactivation.